CD99 engagement: An effective therapeutic strategy for Ewing tumors

Cancer Research

Volumn 60, Issue 18, 2000, Pages 5134-5142

  Scotlandi, K ^a   Baldini, N ^a   Cerisano, V ^a   Manara, M C ^a   Benini, S ^a   Serra, M ^a   Lollini, P L ^a   Nanni, P ^a   Nicoletti, G ^a   Bernard, G ^a   Bernard, A ^a   Picci, P ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD99 ANTIGEN; DOXORUBICIN; FAS ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 013; MONOCLONAL ANTIBODY 0662; MONOCLONAL ANTIBODY MOPC 21; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ADHESION; CONTROLLED STUDY; DRUG CYTOTOXICITY; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; CELL ADHESION MOLECULES; CELL AGGREGATION; CELL DIVISION; COMPARATIVE STUDY; DOXORUBICIN; FEMALE; HUMAN; JURKAT CELLS; MICE; MICE, NUDE; OSTEOSARCOMA; SARCOMA, EWING'S; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0034665335     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ewing's sarcoma, primitive neuroectodermal tumor (PNET)
2. The Ewing family of tumors: A subgroup of small-round-cell tumors defined by specific chimeric transcripts
3. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuro-ectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration
4. Overexpression of the pseudoautosomal gene M1C2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor
5. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy
6. Neoadjuvant chemotherapy for Ewing's sarcoma of bone. No benefit observed after adding iphosphamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase. Results of two sequential studies
7. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study
8. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma
9. Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients
10. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target
11. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice
12. A pseudo-autosomal gene in man
13. The MIC2 gene product: Epitope mapping and structural prediction analysis define an integral membrane protein
14. The E2 antigen, a 32 kDaglycoprotein involved in T cell adhesion process, is the MIC2 gene product
15. A T cell surface molecule different from CD2 is involved in spontaneous rosette formation with erythrocytes
16. + thymocytes
17. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion
18. Apoptosis of immature thymocytes mediated by E2/CD99
19. Engagement of CD99 induces upregulation of TCR and MHC class I and II molecules on the surface of human thymocytes
20. A role for CD99 in T cell activation
21. CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production
22. Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99 (Mic2)
23. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells
24. The E2/MIC2 molecule is defined by cluster of differentiation CD99
25. Multidrug resistance and malignancy in human ostedsarcoma
26. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
27. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition of overexpression of Bcl-2 and Abl
28. Apoptosis signaling by death receptors
29. Activation of programmed cell death by anticancer agents: Cisplatin as a model system
30. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
31. Cell-cycle arrest versus cell death in cancer therapy
32. Antibody-based immunotherapies for Cancer
33. Receptor blockade with monoclonal antibodies as anti-cancer therapy
34. Unconjugated monoclonal antibodies for the treatment of hematologic and solid malignances
35. Molecular biology of cancer: Invasion and metastasis
36. Rho as a regulator of the cytoskeleton
37. Small GTPase RhoD suppresses cell migration and cytokinesis
38. CD99 (MIC2) expression in paediatric B-lineage leukemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis
39. Androgen regulation of the human pseudoautosomal gene MIC2, a potential marker for prostate cancer